EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mitochondrial dysfunction in NPC1 ‐deficiency is not rescued by drugs targeting the glucosylceramidase GBA2 and the cholesterol‐binding proteins TSPO and StARD1

Simon Wheeler iD, Meenakshi Bhardwaj, Victor Kenyon iD, Maria J Ferraz, Johannes M F G Aerts, Dan J Sillence iD

FEBS Letters · 2024

DOI: 10.1002/1873-3468.14802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Letters, 2024. Verfasst von Simon Wheeler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Leicester School of Pharmacy, De Montfort University, Leicester, UK. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Mitochondrial Diseases, Phosphoproteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: De Montfort University, National Niemann-Pick Disease Foundation, Schlumberger Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Niemann–Pick type C disease (NPCD) is a rare neurodegenerative disorder most commonly caused by mutations in the lysosomal protein Niemann–Pick C1 (NPC1), which is implicated in cholesterol export. Mitochondrial insufficiency forms a significant feature of the pathology of this disease, yet studies attempting to address this are rare. The working hypothesis is that mitochondria become overloaded with cholesterol which renders them dysfunctional. We examined two potential protein targets—translocator protein (TSPO) and steroidogenic acute regulatory protein D1 (StARD1)—which are implicated in cholesterol transport to mitochondria, in addition to glucocerbrosidase 2 (GBA2), the target of miglustat, which is currently the only approved treatment for NPCD. However, inhibiting these proteins did not correct the mitochondrial defect in NPC1‐deficient cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Niemann-Pick Disease, Type CMitochondrial DiseasesPhosphoproteinsHumansGlucosylceramidaseIntracellular Signaling Peptides and ProteinsCholesterolNiemann-Pick C1 ProteinReceptors, GABASteroidogenic Acute Regulatory Protein

Stichwörter der Autor:innen

GBA2NPC1Niemann-Pick CStARD1TSPOmitochondria

Substanzen

Steroidogenic Acute Regulatory ProteinGlucosylceramidaseIntracellular Signaling Peptides and ProteinsCholesterolNPC1 protein, humanNiemann-Pick C1 ProteinTSPO protein, humanReceptors, GABAGBA2 protein, humanPhosphoproteins

Autor:innen und Institutionen

  • Leicester School of Pharmacy, De Montfort University, Leicester, UK.
  • Atomwise, San Francisco, CA, USA.
  • Leiden Institute of Chemistry, Leiden University, The Netherlands.

ORCID-Profile: Simon Wheeler, Victor Kenyon, Dan J Sillence

Förderung

  • De Montfort University
  • National Niemann-Pick Disease Foundation
  • Schlumberger Foundation
  • Atomwise

Zitieren

APA

Wheeler, S., Bhardwaj, M., Kenyon, V., Ferraz, M. J., Aerts, J. M. F. G., & Sillence, D. J. (2024). Mitochondrial dysfunction in NPC1 ‐deficiency is not rescued by drugs targeting the glucosylceramidase GBA2 and the cholesterol‐binding proteins TSPO and StARD1. FEBS Letters. https://doi.org/10.1002/1873-3468.14802

Vancouver

Wheeler S, Bhardwaj M, Kenyon V, Ferraz MJ, Aerts JMFG, Sillence DJ. Mitochondrial dysfunction in NPC1 ‐deficiency is not rescued by drugs targeting the glucosylceramidase GBA2 and the cholesterol‐binding proteins TSPO and StARD1. FEBS Letters. 2024. doi:10.1002/1873-3468.14802

BibTeX
@article{Wheeler2024,
  author = {Wheeler, Simon and Bhardwaj, Meenakshi and Kenyon, Victor and Ferraz, Maria J and Aerts, Johannes M F G and Sillence, Dan J},
  title = {Mitochondrial dysfunction in NPC1 ‐deficiency is not rescued by drugs targeting the glucosylceramidase GBA2 and the cholesterol‐binding proteins TSPO and StARD1},
  journal = {FEBS Letters},
  year = {2024},
  doi = {10.1002/1873-3468.14802}
}
Kostenlos starten →